The purpose of this study is to compare post-vaccination reactions between the protein-based Novavax vaccine and the mNEXSPIKE mRNA-1283 vaccine. Specifically, the study aims to determine the rate of participant-reported symptoms associated with each type of vaccine.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
Adults eligible for seasonal COVID-19 vaccine, ages 18 and older Signed informed consent form (ICF) and agree to participate in the study Prior receipt of one or more COVID-19 vaccines
Exclusion Criteria:
* If a person is experiencing a moderate or severe illness or infection (as judged by the study investigator) or has a fever (temperature of 38.0°C or higher) on the day they are supposed to participate in the study, they should not join until they are feeling better and the fever is gone.
* Anyone with a medical or mental health issue, or problems with substance use that might make taking part in the study risky
* People who have had a severe allergic reaction to COVID-19 vaccines in the past
* Those who have been diagnosed with inflammation in or around the heart after receiving a COVID-19 vaccine
* Individuals who have received any other vaccine within a week before joining the study or who plan to get a vaccine on the same day as the study or within 7 days afterward
What they're measuring
1
Number of Participants Reporting ≥1 Systemic Symptom Within 7 Days Post-Vaccination